Details of the Drug Combination

General Information of Drug Combination (ID: DCMWD3I)

• Drug Combination Name: Cabazitaxel + Taxol
• Indication: Invasive ductal carcinoma; Status: Investigative [1]
• Component Drugs:
  Cabazitaxel (DMPAZHC): Small molecular drug
  Taxol (DMUOT9V): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: BT-549
  Zero Interaction Potency (ZIP) Score: 11.81
  Bliss Independence Score: 7.95
  Loewe Additivity Score: 10.06
  LHighest Single Agent (HSA) Score: 13.59

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Cabazitaxel

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Metastatic prostate carcinoma	N.A.	Investigative	[3]

Cabazitaxel Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[8]

Cabazitaxel Interacts with 3 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[9]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Metabolism	[9]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Metabolism	[9]

Cabazitaxel Interacts with 2 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Forkhead box protein O3 (FOXO3)	OTHXQG4P	FOXO3_HUMAN	Affects Expression	[10]
Proline-rich AKT1 substrate 1 (AKT1S1)	OT4JHN4Y	AKTS1_HUMAN	Decreases Expression	[10]

Indication(s) of Taxol

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[4]
Solid tumour/cancer	2A00-2F9Z	Approved	[5]
Pancreatic cancer	2C10	Phase 3	[6]
Gastric adenocarcinoma	2B72	Phase 2	[7]
Ovarian cancer	2C73	Phase 2	[7]

Taxol Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Apoptosis regulator Bcl-2 (BCL-2)	TTJGNVC	BCL2_HUMAN	Modulator	[4]
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Modulator	[4]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Adenocarcinoma	DC7A0VU	DU-145	Investigative	[11]
Adenocarcinoma	DCN2YLS	OVCAR3	Investigative	[11]
Adenocarcinoma	DCDN3AY	A549	Investigative	[11]
Adenocarcinoma	DC9YC2R	HCT-15	Investigative	[11]
Adenocarcinoma	DCZKB1U	HCC-2998	Investigative	[11]
Adenocarcinoma	DCC35YQ	HCT116	Investigative	[11]
Adenocarcinoma	DCA7QKW	HT29	Investigative	[11]
Adult acute myeloid leukemia	DCQLY2Z	HL-60(TB)	Investigative	[11]
Adult T acute lymphoblastic leukemia	DC6EILQ	MOLT-4	Investigative	[11]
Anaplastic large cell lymphoma	DCVGJUQ	SR	Investigative	[11]
Astrocytoma	DCWDW2Q	U251	Investigative	[11]
Astrocytoma	DC9XKWP	SNB-19	Investigative	[11]
Childhood T acute lymphoblastic leukemia	DC6YHW8	CCRF-CEM	Investigative	[11]
Clear cell renal cell carcinoma	DC0EFYW	A498	Investigative	[11]
Clear cell renal cell carcinoma	DCO0RUF	786-0	Investigative	[11]
Cutaneous melanoma	DCDLOIO	SK-MEL-5	Investigative	[11]
Glioma	DCACEGM	SF-539	Investigative	[11]
High grade ovarian serous adenocarcinoma	DCO5OWV	OVCAR-4	Investigative	[11]
High grade ovarian serous adenocarcinoma	DCEXYHR	OVCAR-5	Investigative	[11]
Large cell lung carcinoma	DCO0VXH	NCI-H460	Investigative	[11]
Lung adenocarcinoma	DCZ0FKH	NCI-H522	Investigative	[11]
Malignant melanoma	DCHZH8U	LOX IMVI	Investigative	[11]
Malignant melanoma	DC5D0RI	UACC62	Investigative	[11]
Melanoma	DCNCX28	UACC-257	Investigative	[11]
Minimally invasive lung adenocarcinoma	DCJQUQ1	NCI-H322M	Investigative	[11]
Mixed endometrioid and clear cell carcinoma	DCNJEWA	IGROV1	Investigative	[11]
Plasma cell myeloma	DC5PWQP	RPMI-8226	Investigative	[11]
Prostate carcinoma	DC2BZCV	PC-3	Investigative	[11]
Renal cell carcinoma	DCPHLFE	SN12C	Investigative	[11]
Breast adenocarcinoma	DCFU6FC	MDA-MB-468	Investigative	[1]
Carcinoma	DCNMEQ2	RXF 393	Investigative	[1]
Carcinoma	DCHMBJR	MCF7	Investigative	[1]
Colon carcinoma	DCPPW3P	KM12	Investigative	[1]
Invasive ductal carcinoma	DCPT8ZY	T-47D	Investigative	[1]
Invasive ductal carcinoma	DCS3GV7	HS 578T	Investigative	[1]

References

• [1] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6798).
• [3] Cabazitaxel FDA Label
• [4] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [9] DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
• [10] The triphenyltin carboxylate derivative triphenylstannyl 2-(benzylcarbamoyl)benzoate impedes prostate cancer progression via modulation of Akt/FOXO3a signaling. Toxicol Appl Pharmacol. 2020 Aug 15;401:115091. doi: 10.1016/j.taap.2020.115091. Epub 2020 Jun 7.
• [11] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.